Success Story: EB-1A Approval after RFE for a Synthetic Organic Chemistry Researcher from India
Client’s Testimonial:
"I appreciate all your excellent support and help. I will definitely refer your service to my friends!”
On June 25th, 2026, we received another EB-1A (Alien of Extraordinary Ability) approval for an Associate Research Scientist in the Field of Synthetic Organic Chemistry (Approval Notice).
General Field: Synthetic Organic Chemistry
Position at the Time of Case Filing: Associate Research Scientist
Country of Origin: India
State of Residence at the Time of Filing: Indiana
Approval Notice Date: June 25th, 2026
Processing Time: 9 months, 21 days (Premium Processing Upgrade Requested)
Case Summary:
The client is a highly accomplished researcher specializing in isocoumarin chemistry and acyl anion methodologies. At the time of filing, the client held a Ph.D. in chemistry and was conducting research focused on the design and synthesis of small molecules and oligonucleotide therapeutics. The work integrates chemical synthesis, drug design, and translational research, advancing precision therapeutics for cancer and inflammatory diseases.
The client’s credentials include:
- 19 peer-reviewed journal articles (6 first-authored), 11 conference abstracts, and 1 preprint
- 351 citations across 45 countries
- At least 35 peer-reviewed assignments for leading journals, including editorial board and guest editor service
The client has received strong support from the field, as reflected in 6 recommendation letters from internationally recognized experts. These letters highlight the significance of the client’s contributions, the originality of the research, and the wide impact of the client’s methods on synthetic organic chemistry, including drug development and bioactive molecule synthesis. One expert noted:
“[Client’s] research therefore has inherently important global ramifications, and his work must be permitted to continue without delay.”
The petition demonstrated the client’s contributions of major significance, including the synthesis of novel isocoumarins, 3-glycosylated isocoumarins, and centrolobine via acyl anion chemistry. These works have been widely cited and adopted, providing foundational methods for drug development, total synthesis, and therapeutic design. Peer-review activity and publication in top journals further reinforced the client’s status as a leading expert in the field.
By presenting a cohesive record of original research, citation impact, peer recognition, and independent expert validation, we successfully addressed the RFE and established that the client satisfies EB-1A criteria. USCIS approved the I-140 EB-1A petition on June 25th, 2026.
We congratulate the client on this achievement and wish continued success in advancing synthetic organic chemistry and the development of novel therapeutics in the United States.